Exhibit 99.1

             Rockwell Medical Technologies, Inc. Extends Warrants

    WIXOM, Mich., Dec. 10 /PRNewswire-FirstCall/ -- Rockwell Medical
Technologies, Inc. (Nasdaq: RMTI), a leading, innovative hemodialysis
concentrate manufacturer in the healthcare industry, announced today that it
has extended the expiration date of its publicly traded warrants by twelve
months to January 26, 2006 at 5 p.m. EST.
    Rockwell warrants trade under the symbol RMTIW with an exercise price of
$4.50 per Common Share.  The warrants have a call feature and may be redeemed
by the Company provided the bid price of the Common Shares has been at least
$7.00 for 20 consecutive trading days ending on the third day prior to the
date the notice of redemption is given.
    Rockwell Medical Technologies, Inc. is an innovative leader in
manufacturing, marketing and delivering high-quality dialysis solutions,
powders and ancillary products that improve the quality of care for dialysis
patients.  Dialysis is a process that duplicates kidney function for those
patients whose kidneys have failed to work properly and suffer from chronic
kidney failure, a condition also known as end stage renal disease (ESRD).
There are an estimated 350,000 dialysis patients in the United States and the
incidence of ESRD has increased 6-8% on average each year over the last
decade.  Rockwell's products are used to cleanse the ESRD patient's blood and
replace nutrients in the bloodstream.  Rockwell offers the proprietary Dri-
Sate(R) Dry Acid Mixing System, RenalPure(TM) Liquid Acid, RenalPure(TM)
Powder Bicarbonate, SteriLyte(R) Liquid Bicarbonate, Blood Tubing Sets,
Fistula Needles and a wide range of ancillary dialysis items.  Visit
Rockwell's website at http://www.rockwellmed.com .
    Certain statements in this press release with respect to Rockwell's
business and operations constitute "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995.  These
forward-looking statements reflect management's expectations and are based
upon currently available information.  Management of Rockwell believes the
expectations reflected in the forward-looking statements made in this press
release are based upon reasonable assumptions.  However, certain factors could
occur that might cause actual results to vary.  These include, but are not
limited to, general economic conditions, economic conditions in the
hemodialysis industry, competitive factors and other factors discussed in
Rockwell's reports filed with the Securities and Exchange Commission.  The
forward-looking statements should be considered in light of these risks and
uncertainties.

SOURCE  Rockwell Medical Technologies, Inc.
    -0-                             12/10/2004
    /CONTACT:  Thomas Klema of Rockwell Medical Technologies, Inc.,
+1-248-960-9009/
    /Web site:  http://rockwellmed.com /
    (RMTI)

CO:  Rockwell Medical Technologies, Inc.
ST:  Michigan
IN:  MTC
SU: